CXCL10 Expression Status is Prognostic in Patients with Advanced Thoracic Esophageal Squamous Cell Carcinoma
Authors:
- 13 October 2015
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 23 (3) , 936-942
Abstract
CXCL10, a member of the CXC chemokine family, is known to mediate chemotaxis, apoptosis, angiogenesis, and cell growth. It is also reportedly involved in tKeywords
Funding Information
- JSPS KAKENHI (25870072)
This publication has 31 references indexed in Scilit:
- Phase II Study of Chemoradiotherapy With 5-Fluorouracil and Cisplatin for Stage II–III Esophageal Squamous Cell Carcinoma: JCOG Trial (JCOG 9906)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)Annals of Surgical Oncology, 2011
- Radiotherapy quality assurance review for a multi-center randomized trial of locally advanced esophageal cancer: the Japan Clinical Oncology Group (JCOG) trial 0303International Journal of Clinical Oncology, 2011
- The emerging role of CXCL10 in cancer (Review)Oncology Letters, 2011
- Mesenchymal stem cells within tumour stroma promote breast cancer metastasisNature, 2007
- Whole genome analysis for liver metastasis gene signatures in colorectal cancerInternational Journal of Cancer, 2007
- Neuronal and glioma-derived stem cell factor induces angiogenesis within the brainCancer Cell, 2006
- Surgery Plus Chemotherapy Compared With Surgery Alone for Localized Squamous Cell Carcinoma of the Thoracic Esophagus: A Japan Clinical Oncology Group Study—JCOG9204Journal of Clinical Oncology, 2003
- Improvement in Treatment Results and Long-Term Survival of Patients With Esophageal CancerAnnals of Surgery, 2003
- Improvement in the Results of Surgical Treatment of Advanced Squamous Esophageal Carcinoma During 15 Consecutive YearsAnnals of Surgery, 2000